Alpha Cognition has reported positive top line data from the BEACON real-world study assessing provider-reported outcomes for long-term care residents with mild-to-moderate Alzheimer’s disease treated with Zunveyl.
The Phase IV, observational real-world study results are based on retrospective provider assessments and chart reviews across 162 patients.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It included 21 investigators assessing patients for three to 12 months with Zunveyl, either after prior acetylcholinesterase inhibitor treatment or following discontinuation due to earlier limited efficacy or tolerability.
Findings indicated that 92% of providers observed cognitive improvement while 93% reported improvements in neuropsychiatric symptoms.
Reported outcomes also included delayed initiation or discontinuation of additional psychotropic medications in 80% of patients.
Furthermore, 71% of providers noted favourable changes in activities of daily living (ADLs), and 72% reported improvement across sleep-related outcomes.
Providers observed favourable gastrointestinal tolerability in Zunveyl-treated patients. 98% of participating providers reported a favourable overall treatment experience.
Provider reports also indicated that antipsychotics and anxiolytics were often delayed or discontinued, though the study was not structured to confirm that these changes are attributable to Zunveyl specifically.
The study focused on capturing provider assessments and chart review data from long-term care settings.
All provider observations were made in a non-randomised, uncontrolled environment; therefore, causality between Zunveyl and reported outcomes cannot be established.
The study authors acknowledged the limitations of observational research, including potential bias, confounding variables, clinical variability, and lack of a control group.
Findings may not predict future clinical outcomes or support regulatory or reimbursement decisions without further prospective, controlled trials.
Zunveyl (benzgalantamine) was developed to reduce gastrointestinal exposure, though clinical significance remains established only as described in prescribing information.
Alpha Cognition CEO Michael McFadden said: “We believe that long-term care patients with Alzheimer’s disease remain underrepresented in traditional clinical datasets despite representing a significant and clinically complex treatment population.
“BEACON provides valuable real-world insights into the treatment experience of long-term care patients with Alzheimer’s disease receiving Zunveyl.”
